Marker Therapeutics, Inc.

Tagged: update

TapImmune Provides First Quarter 2017 Corporate and Clinical Update Today

TapImmune is hosting a conference call and live audio webcast today, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.

Read More

TapImmune to Provide First Quarter 2017 Business Update Conference Call and Webcast

TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.

Read More

TapImmune Provides Year End 2016 Corporate and Clinical Update

TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.

Read More

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

TapImmune announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).

Read More

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

TapImmune today announced that the Company will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2016.

Read More

TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application

…JACKSONVILLE, Florida, September 6, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts.

Read More

TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease

…Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.

SEATTLE, WASHINGTON, October 22, 2014 — TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.

Read More